Compare Citius Pharmaceuticals Inc (CTXR) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs RLX Technology Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while RLX Technology Inc trades at $1.98 (market cap $2.42B). The key difference: RLX Technology Inc is far larger — about 165.3× Citius Pharmaceuticals Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | RLX | |
|---|---|---|
Market Cap | $14.64M | $2.42B |
Sector | Health | Technology |
52-Week High | $1.82 | $2.73 |
52-Week Low | $0.53 | $1.79 |
Enterprise Value | $10.86M | $1.05B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
RLX Technology trades at $1.97, up 1.03% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth driven by international expansion, though it missed EPS estimates for three consecutive quarters. RLX maintains strong profitability with a 22.47% net income margin and is debt-free with substantial cash flow from operations.
Outlook is mixed: strong fundamentals and industry growth potential are offset by recent earnings misses and a single analyst hold rating. Key risks include regulatory scrutiny in the vaping sector and execution challenges in global markets. The stock presents a value opportunity but requires monitoring of earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
